Prescient Therapeutics Limited has released a press release.
March 2026 Quarterly Update and Appendix 4C
Earlier from Prescient Therapeutics
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL